Eganelisib (IPI-549) Liposomes, Formulation WNX5.2
2995 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - DLL-0015-A1-10ML
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 10mL
Parameters
| Additional information | 292 mM sucrose, 0.5% DPBS (1X) |
|---|
DLL-0015-A1-10ML
Eganelisib (IPI-549) Liposomes, Formulation WNX5.2
PEGylated liposomes containing PI3Kγ inhibitor Eganelisib (IPI-549). Eganelisib (IPI-549) is a potent and selective PI3Kγ inhibitor (IC50 16 nM) which is reported to exhibit more than 100-fold selectivity over other lipid and protein kinases and potentiate immunotherapy with immune checkpoint inhibitors in mice. IPI-549 is insoluble in aqueous media. This product is a pre-formulated liposomal version of IPI-549 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
2995 €
HY-100716
Eganelisib
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases[1].
376.69 €
DLL-0011-2ML
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
995 €
DLL-0010-10ML
DT-061 (SMAP) Liposomes, Formulation TT-40
PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
2995 €
DLL-0010-2ML
DT-061 (SMAP) Liposomes, Formulation TT-40
PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
995 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025